Vor Biopharma Inc.

Equities

VOR

US9290331084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.81 ^USD	+0.56%		+5.85%	-19.56%

May. 13	Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating	MT
May. 09	Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

March 20, 2024 at 04:05 pm EDT

Vor Biopharma Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 26.26 million compared to USD 23.91 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.53 a year ago.

For the full year, the company reported net loss was USD 117.86 million compared to USD 92.09 million a year ago. Basic loss per share from continuing operations was USD 1.75 compared to USD 2.33 a year ago.

Latest news about Vor Biopharma Inc.

Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating	May. 13	MT
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Vor Biopharma Inc. Appoints Fouad Namouni as Class II Director	May. 02	CI
Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	Mar. 21	MT
Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	Mar. 21	MT
Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 20	CI
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Vor Biopharma Doses First Blood Cancer Patient With Leukemia Treatment, Provides Cash Runway Guidance	Jan. 17	MT
Vor Bio Doses First AML Patient with VCAR33	Jan. 17	CI
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference	Nov. 09	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform	Nov. 02	CI
Wedbush Cuts Vor Biopharma's Price Target to $11 From $18, Keeps Outperform Rating	23-08-11	MT
Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell Small Cap Comp Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000E Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell Small Cap Completeness Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2500 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000E Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000 Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Dynamic Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2500 Value Index	23-06-23	CI

Chart Vor Biopharma Inc.

Duration

Period

More charts

Company Profile

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Companyâs lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Sector

Biotechnology & Medical Research

Calendar

10:30am - H.C. Wainwright BioConnect Investor Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.81 USD

Average target price

14.06 USD

Spread / Average Target

+676.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VOR BIOPHARMA INC.	-19.56%	124M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research